US · Healthcare · Biotechnology
EPS came in at -0.54 against a street estimate of -0.70 — a beat of 22.9%.
Analysts rate Replimune Group Inc a buy (7 buy, 0 hold, 1 sell out of 8) with an average price target of $23.33.
CONFIDENT TUDRIQEV launched strongly, with rapid formulary additions, prescriptions, payer coverage and next-day delivery. Management expects account momentum to build, while withholding revenue guidance and patient-volume metrics until more real-world data emerges. Q2 FY27 The commercial discussion focused on the U.S. melanoma opportunity; management cited approximately 10,000 addressable patients. Analysts focused on launch cadence, treatment conversion, sales-force readiness, injection mix, formulary restrictions and expansion beyond the initial target accounts. Management emphasized rapid delivery and workflows, while declining to quantify patient volumes or revenue yet. 2026-10-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| Baker Bros Advisors LP | 11.72% |
| BlackRock Inc | 9.51% |
| RTW INVESTMENTS, LLC | 7.87% |
| Ridgeback Capital Investments L.p. | 7.76% |
| The Goldman Sachs Group Inc | 4.82% |
| State Street Corp | 4.71% |
| Suvretta Capital Management, LLC | 4.66% |
| Boxer Capital Management, LLC | 4.23% |
| Document | Date |
|---|---|
| Quarterly report · Q2 FY2027 HEADLINE NUMBERS • Revenue was not reported for the six months ended September 30, 2026; TUDRIQEV became available for commercial sale on October 1, | 2026-10-28 |
| Results announced · Q3 FY2027 HEADLINE NUMBERS • Fiscal second-quarter 2027 net loss was $57.1 million, or $0.54 per share, versus a $83.1 million loss, or $0.90 per share, in fis | 2026-10-28 |
| Charter / bylaws change · Q2 FY2027 REPLIMUNE GROUP, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held September 15, 2026 • Authorized common shares increased | 2026-09-16 |
| Quarterly report · Q1 FY2027 REPLIMUNE GROUP, INC. - FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash & Equivalents: $185.4 million as of June 30, | 2026-08-14 |
| Results announced · Q2 FY2027 REPLIMUNE GROUP, INC. – FISCAL Q1 2027 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • FDA Approval & Launch: TUDRIQEV (vusolimogene oderparepvec-wtpg) | 2026-08-14 |
| Company announcement · Q2 FY2027 REPLIMUNE GROUP, INC. - FORM 8-K SUMMARY August 9, 2026 Stock Offering --- HEADLINE NUMBERS • Company raising approximately $140.5 million in net p | 2026-08-10 |
| Company announcement · Q2 FY2027 REPLIMUNE GROUP, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Replimune Group, Inc. (ticker: REPL, Nasdaq) • Filing date: August 6, 2026 • He | 2026-08-07 |
| Company announcement · Q2 FY2027 REPLIMUNE GROUP, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Advisory Committee Vote: FDA's Cellular, Tissue, and Gene Therapies Advisory Committee v | 2026-07-31 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Replimune Group Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.